Results 191 to 200 of about 933,936 (328)

Matrix Metalloproteinase Inhibition in Melanoma. [PDF]

Exp Dermatol
Zhang E, Thakur V, Bedogni B.
europepmc   +1 more source

Interaction between MHC Molecules and brother of regulator of imprinting sites (BORIS) in a melanoma cell line

, 2018
Jamila Alhoderi, Garth Griffiths , Nelson Fernandez, Jamila Alhoderi, Garth Griffiths , Nelson Fernandez   +1 more
openalex   +2 more sources

Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription

Advanced Science, EarlyView.
This study identifies the transcription factor Nuclear Factor I‐B (NFIB) as a key suppressor of liver fibrosis. NFIB expression declines during hepatic stellate cell activation, and its overexpression reduces fibrosis in mice models. The mechanism involves NFIB directly repressing chemokine C─C motif ligand 5 (CCL5), thereby alleviating oxidative ...
Qianqian Chen, Fajuan Rui, Zhiwen Fan, Hongju Yang, Nan Geng, Chenqi Lu, Wenjing Ni, Yue Huan, Junping Shi, Chao Wu, Shengxia Yin, Wei An, Xia Lu, Qianwen Zhao, Jie Li   +14 more
wiley   +1 more source

Aberrant Activation of the Hedgehog Pathway in Cutaneous Melanoma: Therapeutic Potential of Pharmacological Inhibitors. [PDF]

Int J Mol Sci
Papaccio F, Kovacs D, Marrapodi R, Caputo S, Migliano E, Melucci E, Scalera S, Cota C, Maugeri-Saccà M, Bellei B.   +9 more
europepmc   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

Risk Factors for Melanoma Survival: DGCR8 as a Predictive Factor for Mortality in Young Patients. [PDF]

Acta Derm Venereol
Schafer F, Bellolio E, Sepúlveda T, Espinoza M, Orellana JJ, Villaseca MA, Miranda R.   +6 more
europepmc   +1 more source

Melanoma cutâneo e linfonodo sentinela : nível Clark e positividade do linfonodo sentinela

, 2010
Filipe Pereira Madeira, Rafael Bueno Mazzuca, Eduardo Antônio Dalberto, André Alves Valiati, Natasha M. Oliveira, Sara S. Vanazzi, Alceu Migliavaca, Jose Ricardo Guimaraes   +7 more
openalex   +1 more source

A case of disseminated melanoma with esophageal metastasis in a dog.

, 2012
Flaviu Tăbăran, András Nagy, Pompei Bolfă, Annamaria Gal, C. Boari, G. Borza, C. Cătoi   +6 more
openalex   +2 more sources

Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome

Advanced Science, EarlyView.
Pharmacological SUMOylation inhibition (SUMOi) counteracts tumor immune evasion by unmasking an immunogenic HLA‐I peptide and neoepitope repertoire. By restoring HLA‐I ligand availability through increased antigen processing and presentation, enhanced proteasomal cleavage, and modulated TAP1 peptide affinity, SUMOi boosts tumor immunogenicity ...
Uta M. Demel, Anna Meurer, Badeel Kh. Q. Zaghla, Bilge Atay, Daniel Steiert, Luca V. Hummel, Konstandina Isaakidis, Chuanbing Zang, Michael Korenkov, Marlon Schielin, Schayan Yousefian, Shima Mecklenbräuker, Marieluise Kirchner, Simon Haas, Antonia Busse, Philipp Mertins, Stefan Müller, Matthias Wirth, Martin G. Klatt, Ulrich Keller   +19 more
wiley   +1 more source

Malignant Melanoma: Landscape of Molecular Markers. [PDF]

Biomedicines
Winter M, Ebner S, Baum V, Kiil K, Rauschendorf MA, Wild PJ.   +5 more
europepmc   +1 more source